NCI Announces New Cancer Survivorship Training Program

Publication
Article
OncologyONCOLOGY Vol 12 No 2
Volume 12
Issue 2

In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues survivors face.

In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues survivors face.

The training program was developed by NCI’s Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.

To obtain a free copy of the training program, please contact the NCI’s Cancer Information Service at 1 (800) 4-CANCER [1 (800) 422-6237].

Articles in this issue
New Tobacco Industry Strategy Is to Appear Anti-Tobacco, UCSF Study Concludes
Quantitative Assay Provides Effective Method for Monitoring Bladder Cancer
Extension of Human Cell Life-Span Reported
Abnormal DNA Structures May Hold Key to Early Cancer Detection, Treatment
SGO Clinical Practice Guidelines: Introductory Remarks
ACS Issues Action Proposal on Prostate Cancer in African-Americans
HMO vs Fee-for-Service Care for Breast Cancer
Revised Manual on Radiation Oncology Nursing Available
ONS Publishes Manual on Psychosocial Aspects of Oncology Care
Cigarette Smoking Among Adults-United States, 1995
NCI Announces New Cancer Survivorship Training Program
Carmustine Wafer to Be Studied in Newly Diagnosed Malignant Glioma
Thyroid Cancer May Not Be More Serious in Pregnant Women
Beyond Survival: Economic Analyses of Chemotherapy in Advanced, Inoperable NSCLC
Practice Guidelines: Fallopian Tube Cancer
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.